Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Placebo-controlled, Multicentre Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalised for Acute Heart Failure

Next Previous
Search
Trial Profile

A Double-blind, Randomised, Placebo-controlled, Multicentre Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalised for Acute Heart Failure

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Acute heart failure; Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms ATOMIC-AHF
  • Sponsors Amgen

    • Most Recent Events

    • 29 Aug 2022 Results of meta-analysis of 4 trials (NCT02695420, COSMIC-HF, ATOMIC-AHF & GALACTIC-HF) assessing clinical outcomes of omecamtiv mecarbil in patients with Heart Failure with Reduced Ejection Fraction, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 29 Mar 2016 Results published in the Journal of the American College of Cardiology
    • 23 Sep 2013 Additional results presented at a late-breaking clinical trials session at the Heart Failure Society of America Annual Scientific meeting, according to a Cytokinetics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top